


In view of the above, it is submitted that this application is in good order for allowance, and such early action is respectfully solicited. Should matters remain which the Examiner believes could be resolved in a telephone interview, the Examiner is requested to telephone the Applicant's undersigned attorney.

Respectfully submitted,


Charles Berman
Reg. No. 29,249

Date: July 11, 2001

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East
38th Floor
Los Angeles, CA 90067-3024
Phone: (310) 788-5000
FAX: (310) 788-5100

ADDENDUM PAGES

VERSION MARKED TO REFLECT CHANGES

I. CHANGES IN THE TITLE

Please amend the title to read "ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS – HUMAN FRAZZLED (FRZB-1) PROTEIN".

II. CHANGES IN SPECIFICATION

1. The following shows the changes made to the paragraph originally found at page 1, line 14 of the specification:

[This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.] This application is a Divisional of Application Serial No. 09/552,988 filed April 21, 2000, which claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.

III. CHANGES IN THE CLAIMS

6. (Amended) A substantially pure protein characterized by a physiologically active form and comprising an amino acid sequence encoded by the DNA of [SEQ ID NO:4, SEQ ID NO:8, or] SEQ ID NO:10.

7. The protein as in claim 6 having neurotrophic, growth or differentiation factor activity.

8. A composition comprising the protein of claim 6 and a physiologically acceptable carrier with which the protein is admixed.

12. A complex comprising a substantially pure frzb-1 protein complexed with at least one Wnt protein.